Table 5 Relevant patients’ characteristics at the time of accrual in clinical trials on dendritic cell vaccination in glioblastoma multiforme

^aPrins⁸

(7%; 77%; 20%; 7%)

(60%; 33%; 7%)^d

^aArdon⁹

N/A

(12%/87%/0%)

^bSampson²⁵

(39%; 39%; 22%; 0%)

(28%/72%/0%)^d

^cPhuphanich²⁶

(12%; 62%; 12%; 12%)

(19%/69%/12%)^d

Present data (intention-to-treat)

(6%; 23%; 36%; 36%)

(10%/42%/48%)